APA (7th ed.) Citation

Mizuta, H., Okada, K., Araki, M., Adachi, J., Takemoto, A., Kutkowska, J., . . . Katayama, R. (2021). Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nature Communications, 12(1), . https://doi.org/10.1038/s41467-021-21396-w

Chicago Style (17th ed.) Citation

Mizuta, Hayato, et al. "Gilteritinib Overcomes Lorlatinib Resistance in ALK-rearranged Cancer." Nature Communications 12, no. 1 (2021). https://doi.org/10.1038/s41467-021-21396-w.

MLA (9th ed.) Citation

Mizuta, Hayato, et al. "Gilteritinib Overcomes Lorlatinib Resistance in ALK-rearranged Cancer." Nature Communications, vol. 12, no. 1, 2021, https://doi.org/10.1038/s41467-021-21396-w.